EAN 2025: Patients with Alzheimer’s deserve early diagnosis and causal treatment

Professor Frank Jessen, MD, Associate Researcher and Group Leader at DZNE, outlines how upcoming disease-modifying treatments for Alzheimer’s require a shift toward earlier diagnosis. He points to blood-based biomarkers and digital cognitive tools as key enablers, and calls for new care pathways and greater awareness—drawing inspiration from advances in fields like MS, arthritis and cancer.